Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report)’s stock price fell 0.5% on Monday . The company traded as low as $2.20 and last traded at $2.20. 1,670 shares were traded during mid-day trading, an increase of 34% from the average session volume of 1,248 shares. The stock had previously closed at $2.21.
Silence Therapeutics Price Performance
The business has a 50-day simple moving average of $1.79 and a two-hundred day simple moving average of $1.78.
Silence Therapeutics Company Profile
Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.
The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.
Featured Articles
- Five stocks we like better than Silence Therapeutics
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
